Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 3, 2011, Pages 272-285

  Miljkovic, Milena M ^a   Dobric, Silva ^b   Dragojevic Simic, Viktorija ^b  

^a Medicines and Medical Devices Agency of Serbia   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Causality assessment; Commonly used scales; Hepatotoxicity; Reliability; Usefulness

Indexed keywords

ALPHA2A INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; AZITHROMYCIN; CARBAMAZEPINE; CIPROFIBRATE; CIPROFLOXACIN; CISPLATIN; CLOZAPINE; ERYTHROMYCIN; FLUCONAZOLE; GADOLINIUM PENTETATE MEGLUMINE; HALOPERIDOL; HUMAN GROWTH HORMONE; IMATINIB; ISONIAZID; METHOTREXATE; MIRTAZAPINE; NAPROXEN; NIMESULIDE; PRAVASTATIN; RIFAMPICIN; RISPERIDONE; RITUXIMAB; SEVOFLURANE; SIMVASTATIN; TAMOXIFEN; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ABDOMINAL PAIN; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ACUTE PANCREATITIS; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CHOLESTASIS; CLINICAL ASSESSMENT; COMA; COMPARATIVE STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; EOSINOPHILIA; FATIGUE; FATTY LIVER; FEMALE; FOOT PARESTHESIA; HEPATITIS; HEPATITIS B; HEPATOMEGALY; HEPATORENAL SYNDROME; HEPATOSPLENOMEGALY; HUMAN; JAUNDICE; KNEE PAIN; LEUKOPENIA; LIVER NECROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARESTHESIA; PETECHIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RATING SCALE; SCHOOL CHILD; SCLERA DISEASE; SCORING SYSTEM; SHIVERING; SIDE EFFECT; SKIN DISCOLORATION; SUBICTERIC SCLERA; THROMBOCYTOPENIA; TOXIC HEPATITIS; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CAUSALITY; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951965864     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2081     Document Type: Article

References (28)

1. Lee WM. Medical progress: drug-induced hepatotoxicity. N Engl J Med 2003; 349(5): 474-485.
2. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005; 33(1): 155-164.
3. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25: 1135-1151.
4. Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega C, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007; 13(3): 329-340.
5. Lucena MI, Garcia-Cortes M, Cueto R, Lopez Duran JL, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008; 22(1): 141-158.
6. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66(6): 758-766.
7. Andrade RJ, Robles M, Ortiz N, Lucena MI. Rechallenge in hepatotoxicity: proof of concept or therapeutic accident? Rev Esp Enferm Dig 2008; 100(5): 255-258.
8. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007; 6: 673-684.
9. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 2005; 172(3): 367-379.
10. Navarro VJ, Senior JR. Current concepts: drug-related hepatotoxicity. N Engl J Med 2006; 354(7): 731-739.
11. Holt MP, Ju C. Mechanisms of drug-induced liver injury. Am Assoc Pharm Sci J 2006; 8(1): E48-E55.
12. Meyboom RHB, Hekster YA, Egberts ACG, Gribnau FWJ, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17(6): 374-389. Reprint Collection, Update 2005.
13. Agbabiaka TA, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions. Drug Saf 2008; 31: 21-37.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
15. Benichou C, Danan G. A new method for drug causality assessment: RUCAM. In: Adverse Drug Reactions. A Practical Guide to Diagnosis and Management. Benichou C (ed). John Wiley & Sons Ltd.: Chichester, 1994; p. 277-287.
16. Maria VA, Victorino RM, Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26(3): 664-669.
17. Watanabe M, Shibuya A. Validity of a new diagnostic scale for drug-induced liver injury in Japan - comparison with two initial scales. Hepatol Res 2004; 30(3): 148-154.
18. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reaction. J Hepatol 2000; 33: 949-952.
19. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14(44): 6774-6785.
20. World Health Organization Collaborating Cente for Drugs Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index Including Defined Daily Doses (DDDs) for Plain Substances. Oslo: World Health Organization Collaborating Cente for Drugs Statistics Methodology, 2009.
21. Volumen 9A. Pharmacovigilance. The Rules Governing Medicinal Products in the European Union. Guidelines on Pharmacovigilance for Medicinal Products for Human Use. Brisel: European Commission, 2007.
22. Sim J, Wright CC. The Kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005; 85: 257-268.
23. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive. Acta Pædiatr 2006; 96: 338-341.
24. Garcia-Cortes M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008; 27(9): 780-789.
25. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
26. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez de. la. Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33(1): 123-130.
27. Lewis JH, Larrey D, Olsson R, Lee WM, Frison L, Keisu M. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther. 2008; 46(7): 327-329.
28. Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Drug-Induced Liver Injury Network (DILIN). Hepatology 2008; 48(4): 1175-1183.